An Open-Label, Dose-Finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 [motesanib] With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclitaxel in the Treatment of Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

An Open-Label, Dose-Finding Study to Evaluate the Safety and Pharmacokinetics (PK) of AMG 706 [motesanib] With Carboplatin/Paclitaxel, AMG 706 With Panitumumab and AMG 706 With Panitumumab and Carboplatin/Paclitaxel in the Treatment of Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Mar 2016

At a glance

  • Drugs Motesanib (Primary) ; Carboplatin; Paclitaxel; Panitumumab
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Amgen
  • Most Recent Events

    • 21 Mar 2014 The study design has been changed from single group assignment to parallel group assignment and primary endpoint has been changed from safety and pharmacokinetics to pharmacokinetics only as reported by ClinicalTrials.gov record.
    • 21 Mar 2014 The study design has been changed from single group assignment to parallel group assignment and primary endpoint has been changed from safety and pharmacokinetics to pharmacokinetics only as reported by ClinicalTrials.gov record.
    • 25 Aug 2009 Actual end date (Mar 2007) and actual number of patients (51) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top